
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
almost 30 years ago
Introductionalmost 30 years ago
Gatekeepers and Managed Care: Too Much of a Good Thing?almost 30 years ago
MANAGED CARE CLINICAL CORNER: Chest Painalmost 30 years ago
Selected Abstracts





